Detailed explanation of precautions for using vibutuximab

As an important anti-cancer drug, Vibutuximab (also known as Bentuximab, trade name: Adcetris) plays a key role in the treatment of lymphoma and other cancers. However, there are many precautions that need to be strictly followed during its use to ensure patient safety and effectiveness of treatment.

Concomitant use of vilbutuximab with bleomycin is contraindicated due to the risk of pulmonary toxicity (e.g., interstitial infiltration and/or inflammation). Patients who are allergic to velbutuximab should never be treated with this drug. To ensure that vilbutuximab is safe for patients, it is important for patients to tell their doctors in detail about their medical history, including whether they have diabetes, liver disease, kidney disease, or peripheral vascular disease (such as Raynaud's syndrome). These diseases may affect the metabolism and tolerance of drugs in the body and increase the risk of adverse reactions.

Animal studies and the drug's mechanism of action indicate that velbutuximab can cause fetal harm. Therefore, the pregnancy status of females of reproductive potential needs to be verified before initiating treatment. It is recommended that women of childbearing potential take effective contraceptive measures during treatment and for 2 months after the last dose of the drug, and report pregnancy as soon as possible. At the same time, the drug may damage sperm and testicular tissue, causing genetic abnormalities. Men who are sexual partners of female partners of reproductive potential should use effective contraceptive measures during treatment and for 4 months after the last dose of the drug.

In addition, velbutuximab may cause serious adverse reactions in breastfed children, such as cytopenias, neurological or gastrointestinal toxicity, so patients are not recommended to breastfeed during treatment. Additionally, this drug may lower blood cell counts, requiring frequent blood tests, which may delay cancer treatment depending on the results. If the patient requires surgery, the surgeon should be informed that the drug is being used and that the drug may need to be stopped for a period of time.

In short, velbutuximab has a significant effect in treating cancer, but the above precautions must be strictly observed during use. Patients should maintain close communication with their doctors, truthfully inform them of their conditions, and follow the doctor's instructions for treatment to ensure the safety and effectiveness of treatment to the greatest extent.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris